Combined effects of lapatinib and cisplatin on colony formation of head and neck squamous cell carcinoma

Anticancer Research

Volumn 32, Issue 8, 2012, Pages 3191-3199

  Schrader, Christoph ^a   Boehm, Andreas ^a   Reiche, Anett ^a   Diet, Andreas ^a   Mozet, Christian ^a   Wichmann, Gunnar ^a  

^a UNIVERSITY HOSPITAL LEIPZIG   (Germany)

Author keywords

Cisplatin; FLAVINO assay; HNSCC; Lapatinib; Predictive testing; Tykerb

Indexed keywords

CISPLATIN; LAPATINIB;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; COLONY FORMATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG EFFECT; DRUG MECHANISM; DRUG POTENTIATION; DRUG RESPONSE; FEMALE; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; HUMAN CELL; MALE; PRIORITY JOURNAL;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; CISPLATIN; HEAD AND NECK NEOPLASMS; HUMANS; INHIBITORY CONCENTRATION 50; QUINAZOLINES;

EID: 84865692678     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Parkin DM, Bray F, Ferlay J and Pisani P: Global cancer statistics, 2002. CA Cancer J Clin 55: 74-108, 2005.
2. Sant M, Allemani C, Santaquilani M, Knijn A, Marchesi F and Capocaccia R: EUROCARE-4. Survival of cancer patients diagnosed in 1995-1999. Results and commentary. Eur J Cancer 45: 931-991, 2009.
3. Dietz A, Weber A, Dollner R and Hildebrandt G: Decision making in non resectable head and neck tumours. Laryngorhinootologie 84: 200-206; quiz 207-210, 2005.
4. Dassonville O, Formento JL, Francoual M, Ramaioli A, Santini J, Schneider M, Demard F and Milano G: Expression of epidermal growth factor receptor and survival in upper aerodigestive tract cancer. J Clin Oncol 11: 1873-1878, 1993.
5. Grandis J, Melhem MF, Gooding WE, Day R, Holst VA, Wagener MM, Drenning SD and Tweardy DJ: Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival. J Natl Cancer Inst 90: 824-832, 1998.
6. Ang KK, Berkey BA, Tu X, Zhang HZ, Katz R, Hammond EH, Fu KK and Milas L: Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res 62: 7350-7356, 2002.
7. Rogers SJ, Harrington KJ, Rhys-Evans P, O-charoenrat P and Eccles SA: Biological significance of c-erbB family oncogenes in head and neck cancer. Cancer Metastasis Rev 24: 47-69, 2005.
8. Vermorken JB, Mesia R, Rivera F, Remenar E, Kawecki A, Rottey S, Erfan J, Zabolotnyy D, Kienzer HR, Cupissol D, Peyrade F, Benasso M, Vynnychenko I, De RD, Bokemeyer C, Schueler A, Amellal N and Hitt R: Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 359: 1116-1127, 2008.
9. Dietz A, Boehm A, Horn IS, Kruber P, Bechmann I, Golusinski W, Niederwieser D, Dollner R, Remmerbach TW, Wittekind C, Dietzsch S, Hildebrandt G and Wichmann G: Assay-based response evaluation in head and neck oncology: requirements for better decision making. Eur Arch Otorhinolaryngol, 2010.
10. Desoize B, Berthiot G, Manot L, Coninx P and Dumont P: Evaluation of a prediction model of cisplatin dose based on total platinum plasma concentration. Eur J Cancer 32A: 1734-1738, 1996.
11. Jin ZJ: About the evaluation of drug combination. Acta Pharmacol Sin 25: 146-147, 2004.
12. Wichmann G, Horn IS, Boehm A, Mozet C, Tschop K, Dollner R and Dietz A: Single tissue samples from head and neck squamous cell carcinomas are representative regarding the entire tumor's chemosensitivity to cisplatin and docetaxel. Onkologie 32: 264-272, 2009.
13. Baselga J: Why the epidermal growth factor receptor? The rationale for cancer therapy. Oncologist 7(Suppl 4): 2-8, 2002.
14. Mendelsohn J and Baselga J: Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin Oncol 21: 2787-2799, 2003.
15. Kim JW, Kim HP, Im SA, Kang S, Hur HS, Yoon YK, Oh DY, Kim JH, Lee DS, Kim TY and Bang YJ: The growth inhibitory effect of lapatinib, a dual inhibitor of EGFR and HER2 tyrosine kinase, in gastric cancer cell lines. Cancer Lett 272: 296-306, 2008.
16. Kondo N, Tsukuda M, Ishiguro Y, Kimura M, Fujita K, Sakakibara A, Takahashi H, Toth G and Matsuda H: Antitumor effects of lapatinib (GW572016), a dual inhibitor of EGFR and HER-2, in combination with cisplatin or paclitaxel on head and neck squamous cell carcinoma. Oncol Rep 23: 957-963, 2010.
17. Fischer SJ, Benson LM, Fauq A, Naylor S and Windebank AJ: Cisplatin and dimethyl sulfoxide react to form an adducted compound with reduced cytotoxicity and neurotoxicity. Neurotoxicology - Epub 29: 444-452, 2008.
18. Burris HA, Taylor CW, Jones SF, Koch KM, Versola MJ, Arya N, Fleming RA, Smith DA, Pandite L, Spector N and Wilding G: A phase I and pharmacokinetic study of oral lapatinib administered once or twice daily in patients with solid malignancies. Clin Cancer Res 15: 6702-6708, 2009.
19. Burris HA, Hurwitz HI, Dees EC, Dowlati A, Blackwell KL, O'Neil B, Marcom PK, Ellis MJ, Overmoyer B, Jones SF, Harris JL, Smith DA, Koch KM, Stead A, Mangum S and Spector NL: Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas. J Clin Oncol 23: 5305-5313, 2005.
20. Harrington KJ, El-Hariry IA, Holford CS, Lusinchi A, Nutting CM, Rosine D, Tanay M, Deutsch E, Matthews J, D'Ambrosio C, Turner SJ, Pandeshwara JS and Bourhis J: Phase I study of lapatinib in combination with chemoradiation in patients with locally advanced squamous cell carcinoma of the head and neck. J Clin Oncol 27: 1100-1107, 2009.
21. Boehm A, Wichmann G, Mozet C and Dietz A: [Current therapy options in recurrent head and neck cancer]. HNO 58: 762-769, 2010. doi:10.1007/s00106-010- 2156-0.
22. McHugh LA, Sayan AE, Mejlvang J, Griffiths TR, Sun Y, Manson MM, Tulchinsky E, Mellon JK and Kriajevska M: Lapatinib, a dual inhibitor of ErbB-1/-2 receptors, enhances effects of combination chemotherapy in bladder cancer cells. Int J Oncol 34: 1155-1163, 2009.
23. Mimeault M, Hauke R, Mehta PP and Batra SK: Recent advances in cancer stem/progenitor cell research: therapeutic implications for overcoming resistance to the most aggressive cancers. J Cell Mol Med 11: 981-1011, 2007.
24. Czembirek C, Eder-Czembirek C, Erovic BM, Turhani D, Selzer E and Thurnher D: Inhibition of cytotoxicity of cisplatin by cyclooxygenase-2 inhibitor nimesulide in head and neck cancer cell lines. Oncol Rep 14: 1523-1526, 2005.
25. Saigal B, Glisson BS and Johnson FM: Dose-dependent and sequence-dependent cytotoxicity of erlotinib and docetaxel in head and neck squamous cell carcinoma. Anticancer Drugs 19: 465-475, 2008.